Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

VERAPAMIL HCL

9 general benefit · 5 not a benefit

Other products in the same Health Canada class (C08D) — coverage varies; not interchangeable

  • Diltiazem (Tiazac XC): general benefit, Not a benefit

AA-Verap · DIN 00782483 · 80mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AA-Verap · DIN 00782483 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Daily cost (source): $0.8205 Health Canada: Marketed since 2026-03-24 · brand AA-VERAP · ATC C08DA01 VERAPAMIL · form Tablet · route Oral · ingredients VERAPAMIL HYDROCHLORIDE 80 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

AA-Verap: Formulary list price $0.2735/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2735 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10034 · Verify on the e-Formulary ↗ (DIN 00782483)

Source record
DIN 00782483: AA-Verap Raw flags: chronicUseMed=Y, sec3=Y Item: 240400051; group id 293; item number 0635; lccId None; manufacturer id AAP Source form: Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2735; ministry $0.2735 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00782483 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10034
Interchangeable products
Isoptin · DIN 00554316 · not recorded Mylan-Verapamil · DIN 02237921 · $0.2735
Shortage status: active shortage (reported 2026-09-01, estimated to end 2026-09-25, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00782483
Shortage record checked 2026-09-13T08:10:21.292534+00:00

AA-Verap · DIN 00782491 · 120mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AA-Verap · DIN 00782491 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Daily cost (source): $1.2750 Health Canada: Marketed since 2026-03-24 · brand AA-VERAP · ATC C08DA01 VERAPAMIL · form Tablet · route Oral · ingredients VERAPAMIL HYDROCHLORIDE 120 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

AA-Verap: Formulary list price $0.4250/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4250 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9940 · Verify on the e-Formulary ↗ (DIN 00782491)

Source record
DIN 00782491: AA-Verap Raw flags: chronicUseMed=Y, sec3=Y Item: 240400050; group id 293; item number 0636; lccId None; manufacturer id AAP Source form: Tab; strength: 120mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4250; ministry $0.4250 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00782491 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9940
Interchangeable products
Isoptin · DIN 00554324 · not recorded Mylan-Verapamil · DIN 02237922 · $0.4250
Shortage status: resolved shortage (ended 2026-03-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00782491
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Isoptin SR · DIN 01907123 · 120mg · LA tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Isoptin SR (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Isoptin SR · DIN 01907123 Manufacturer: BGP Pharma ULC; listing date 2007-09-04 Health Canada: Marketed since 2017-12-18 · brand ISOPTIN SR · ATC C08DA01 VERAPAMIL · form Tablet (extended-release) · route Oral · ingredients VERAPAMIL HYDROCHLORIDE 120 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Isoptin SR: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11534 · Verify on the e-Formulary ↗ (DIN 01907123)

Source record
DIN 01907123: Isoptin SR Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240800271; group id 359; item number 0837; lccId None; manufacturer id BGP Source form: LA Tab; strength: 120mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01907123 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11534
Interchangeable products
Apo-Verap SR · DIN 02246893 · not recorded Mylan-Verapamil SR · DIN 02210347 · not recorded
Shortage status: resolved shortage (ended 2024-05-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01907123
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mylan-Verapamil SR · DIN 02210347 · 120mg · LA tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mylan-Verapamil SR · DIN 02210347 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2007-10-03 Health Canada: Marketed since 2022-06-13 · brand MYLAN-VERAPAMIL SR · ATC C08DA01 VERAPAMIL · form Tablet (extended-release) · route Oral · ingredients VERAPAMIL HYDROCHLORIDE 120 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20018 · Verify on the e-Formulary ↗ (DIN 02210347)

Source record
DIN 02210347: Mylan-Verapamil SR Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240800271; group id 359; item number 0837; lccId None; manufacturer id MYL Source form: LA Tab; strength: 120mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.6900; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02210347 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20018
Interchangeable products
Apo-Verap SR · DIN 02246893 · not recorded Isoptin SR · DIN 01907123 · not recorded
Shortage status: resolved shortage (ended 2026-05-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02210347
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Verap SR · DIN 02246894 · 180mg · LA tablet

General benefitDormant since 2017-08-04 · checked 2026-09-02 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Verap SR · DIN 02246894 Manufacturer: Apotex Inc.; listing date 2004-04-06 Daily cost (source): $0.5204 Health Canada: Dormant since 2017-08-04 · brand APO-VERAP SR · ATC C08DA01 VERAPAMIL · form Tablet (extended-release) · route Oral · ingredients VERAPAMIL HYDROCHLORIDE 180 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Verap SR: Formulary list price $0.5204/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5204 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71121 · Verify on the e-Formulary ↗ (DIN 02246894)

Source record
DIN 02246894: Apo-Verap SR Raw flags: chronicUseMed=Y, sec3=Y Item: 240800197; group id 359; item number 0838; lccId None; manufacturer id APX Source form: LA Tab; strength: 180mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.5204; ministry $0.5204 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246894 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71121
Interchangeable products
Isoptin SR · DIN 01934317 · $0.5204 Mylan-Verapamil SR · DIN 02450488 · $0.5204
Shortage status: active shortage (reported 2015-04-17, last updated 2019-12-04) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246894
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2017-08-04 — choose a marketed DIN from the same-category list.

Isoptin SR · DIN 01934317 · 180mg · LA tablet

General benefitDormant since 2021-08-10 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Isoptin SR (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Isoptin SR · DIN 01934317 Manufacturer: BGP Pharma ULC; listing date 1996-10-01 Daily cost (source): $2.0939 Health Canada: Dormant since 2021-08-10 · brand ISOPTIN SR · ATC C08DA01 VERAPAMIL · form Tablet (extended-release) · route Oral · ingredients VERAPAMIL HYDROCHLORIDE 180 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.5204 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15585 · Verify on the e-Formulary ↗ (DIN 01934317)

Source record
DIN 01934317: Isoptin SR Raw flags: chronicUseMed=Y, sec3=Y Item: 240800197; group id 359; item number 0838; lccId None; manufacturer id BGP Source form: LA Tab; strength: 180mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $2.0939; ministry $0.5204 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01934317 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15585
Interchangeable products
Apo-Verap SR · DIN 02246894 · $0.5204 Mylan-Verapamil SR · DIN 02450488 · $0.5204
Shortage status: active shortage (reported 2020-08-10, last updated 2020-08-12) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01934317
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2021-08-10 — choose a marketed DIN from the same-category list.

Mylan-Verapamil SR · DIN 02450488 · 180mg · LA tablet

General benefitDormant since 2024-03-11 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Verapamil SR · DIN 02450488 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2016-11-30 Daily cost (source): $0.5204 Health Canada: Dormant since 2024-03-11 · brand MYLAN-VERAPAMIL SR · ATC C08DA01 VERAPAMIL · form Tablet (extended-release) · route Oral · ingredients VERAPAMIL HYDROCHLORIDE 180 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Verapamil SR: Formulary list price $0.5204/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5204 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93662 · Verify on the e-Formulary ↗ (DIN 02450488)

Source record
DIN 02450488: Mylan-Verapamil SR Raw flags: chronicUseMed=Y, sec3=Y Item: 240800197; group id 359; item number 0838; lccId None; manufacturer id MYL Source form: LA Tab; strength: 180mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.5204; ministry $0.5204 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02450488 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93662
Interchangeable products
Apo-Verap SR · DIN 02246894 · $0.5204 Isoptin SR · DIN 01934317 · $0.5204
Shortage status: active shortage (reported 2022-09-07, last updated 2024-02-22) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02450488
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2024-03-11 — choose a marketed DIN from the same-category list.

Isoptin SR · DIN 00742554 · 240mg · LA tablet

General benefitDormant since 2021-08-31 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Isoptin SR (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Isoptin SR · DIN 00742554 Manufacturer: BGP Pharma ULC; listing date 1996-10-01 Daily cost (source): $2.7924 Health Canada: Dormant since 2021-08-31 · brand ISOPTIN SR · ATC C08DA01 VERAPAMIL · form Tablet (extended-release) · route Oral · ingredients VERAPAMIL HYDROCHLORIDE 240 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $1.7143 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9264 · Verify on the e-Formulary ↗ (DIN 00742554)

Source record
DIN 00742554: Isoptin SR Raw flags: chronicUseMed=Y, sec3=Y Item: 240800128; group id 359; item number 0839; lccId None; manufacturer id BGP Source form: LA Tab; strength: 240mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $2.7924; ministry $1.7143 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00742554 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9264
Interchangeable products
Mylan-Verapamil SR · DIN 02450496 · $1.7143
Shortage status: active shortage (reported 2020-01-24, last updated 2021-08-31) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00742554
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2021-08-31 — choose a marketed DIN from the same-category list.

Mylan-Verapamil SR · DIN 02450496 · 240mg · LA tablet

General benefitDormant since 2024-03-11 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mylan-Verapamil SR · DIN 02450496 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2016-10-27 Daily cost (source): $1.7143 Health Canada: Dormant since 2024-03-11 · brand MYLAN-VERAPAMIL SR · ATC C08DA01 VERAPAMIL · form Tablet (extended-release) · route Oral · ingredients VERAPAMIL HYDROCHLORIDE 240 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Verapamil SR: Formulary list price $1.7143/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.7143 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93663 · Verify on the e-Formulary ↗ (DIN 02450496)

Source record
DIN 02450496: Mylan-Verapamil SR Raw flags: chronicUseMed=Y, sec3=Y Item: 240800128; group id 359; item number 0839; lccId None; manufacturer id MYL Source form: LA Tab; strength: 240mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.7143; ministry $1.7143 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02450496 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93663
Interchangeable products
Isoptin SR · DIN 00742554 · $1.7143
Shortage status: active shortage (reported 2022-09-07, last updated 2023-03-27) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02450496
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2024-03-11 — choose a marketed DIN from the same-category list.

Apo-Verap SR · DIN 02246893 · 120mg · LA tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since 2017-08-04 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Verap SR · DIN 02246893 Manufacturer: Apotex Inc.; listing date 2007-09-04 Health Canada: Dormant since 2017-08-04 · brand APO-VERAP SR · ATC C08DA01 VERAPAMIL · form Tablet (extended-release) · route Oral · ingredients VERAPAMIL HYDROCHLORIDE 120 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71120 · Verify on the e-Formulary ↗ (DIN 02246893)

Source record
DIN 02246893: Apo-Verap SR Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240800271; group id 359; item number 0837; lccId None; manufacturer id APX Source form: LA Tab; strength: 120mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.6900; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246893 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71120
Interchangeable products
Isoptin SR · DIN 01907123 · not recorded Mylan-Verapamil SR · DIN 02210347 · not recorded
Shortage status: active shortage (reported 2015-04-17, last updated 2019-12-04) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246893
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2017-08-04 — choose a marketed DIN from the same-category list.

Mylan-Verapamil · DIN 02237921 · 80mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2024-04-11 — choose a marketed DIN from the same-category list.Discontinued 2024-04-11 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-04-11 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-04-11 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mylan-Verapamil · DIN 02237921 Manufacturer: Mylan Pharmaceuticals ULC; listing date 1999-04-15 Daily cost (source): $0.8205 Health Canada: Cancelled post market since 2024-04-11 · brand MYLAN-VERAPAMIL · ATC C08DA01 VERAPAMIL · form Tablet · route Oral · ingredients VERAPAMIL HYDROCHLORIDE 80 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Verapamil: Formulary list price $0.2735/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2735 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61286 · Verify on the e-Formulary ↗ (DIN 02237921)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02237921). DIN 02237921: Mylan-Verapamil Raw flags: chronicUseMed=Y, dinStatus=E, sec3=Y Item: 240400051; group id 293; item number 0635; lccId None; manufacturer id MYL Source form: Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); DIN status E, meaning unconfirmed Source prices (unrounded): $0.2735; ministry $0.2735 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237921 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61286
Interchangeable products
AA-Verap · DIN 00782483 · $0.2735 Isoptin · DIN 00554316 · not recorded
Shortage status: discontinued (2024-04-11, reported by MYLAN PHARMACEUTICALS ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02237921
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-04-11 — choose a marketed DIN from the same-category list.

Mylan-Verapamil · DIN 02237922 · 120mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2024-04-11 — choose a marketed DIN from the same-category list.Discontinued 2024-04-11 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-04-11 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-04-11 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mylan-Verapamil · DIN 02237922 Manufacturer: Mylan Pharmaceuticals ULC; listing date 1999-04-15 Daily cost (source): $1.2750 Health Canada: Cancelled post market since 2024-04-11 · brand MYLAN-VERAPAMIL · ATC C08DA01 VERAPAMIL · form Tablet · route Oral · ingredients VERAPAMIL HYDROCHLORIDE 120 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Verapamil: Formulary list price $0.4250/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4250 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61287 · Verify on the e-Formulary ↗ (DIN 02237922)

Source record
DIN 02237922: Mylan-Verapamil Raw flags: chronicUseMed=Y, sec3=Y Item: 240400050; group id 293; item number 0636; lccId None; manufacturer id MYL Source form: Tab; strength: 120mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4250; ministry $0.4250 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237922 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61287
Interchangeable products
AA-Verap · DIN 00782491 · $0.4250 Isoptin · DIN 00554324 · not recorded
Shortage status: resolved shortage (ended 2024-02-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02237922
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-04-11 — choose a marketed DIN from the same-category list.

Isoptin · DIN 00554316 · 80mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-07-31 — choose a marketed DIN from the same-category list.Discontinued 2007-07-31 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-07-31 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2007-07-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Isoptin · DIN 00554316 Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01 Daily cost (source): $0.8205 Health Canada: Cancelled post market since 2007-07-31 · brand ISOPTIN TAB 80MG · ATC C08DA01 VERAPAMIL · form Tablet · route Oral · ingredients VERAPAMIL HYDROCHLORIDE 80 MG · company Abbott laboratories, limited · schedule Prescription
Check this DIN again · Health Canada product record

Isoptin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4757 · Verify on the e-Formulary ↗ (DIN 00554316)

Source record
DIN 00554316: Isoptin Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240400051; group id 293; item number 0635; lccId None; manufacturer id ABB Source form: Tab; strength: 80mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00554316 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4757
Interchangeable products
AA-Verap · DIN 00782483 · $0.2735 Mylan-Verapamil · DIN 02237921 · $0.2735
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00554316
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2007-07-31 — choose a marketed DIN from the same-category list.

Isoptin · DIN 00554324 · 120mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-07-31 — choose a marketed DIN from the same-category list.Discontinued 2007-07-31 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-07-31 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2007-07-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Isoptin · DIN 00554324 Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01 Daily cost (source): $1.2750 Health Canada: Cancelled post market since 2007-07-31 · brand ISOPTIN TAB 120MG · ATC C08DA01 VERAPAMIL · form Tablet · route Oral · ingredients VERAPAMIL HYDROCHLORIDE 120 MG · company Abbott laboratories, limited · schedule Prescription
Check this DIN again · Health Canada product record

Isoptin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4758 · Verify on the e-Formulary ↗ (DIN 00554324)

Source record
DIN 00554324: Isoptin Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240400050; group id 293; item number 0636; lccId None; manufacturer id ABB Source form: Tab; strength: 120mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00554324 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4758
Interchangeable products
AA-Verap · DIN 00782491 · $0.4250 Mylan-Verapamil · DIN 02237922 · $0.4250
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00554324
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2007-07-31 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered

Matched class: 24:04 Cardiac Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE 24:00 CARDIOVASCULAR DRUGS

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:04 Cardiac Drugs

DILTIAZEM HCL

· 93 products · General benefit (91), Listed, not a benefit (2) · strengths: 120mg, 180mg, 240mg, 300mg, 360mg, 30mg, 60mg · ER Tab, LA Cap, SR Cap, Tab

ACEBUTOLOL HCL

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab

AMIODARONE HCL

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab

AMLODIPINE

· 56 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

DIGOXIN

· 7 products · General benefit · strengths: 0.05mg/mL, 0.0625mg, 0.125mg · O/L, Tab

DISOPYRAMIDE

· 3 products · Listed, not a benefit (1), General benefit (1), Temporary benefit (1) · strengths: 100mg · Cap

FLECAINIDE ACETATE

· 14 products · Listed, not a benefit (2), General benefit (12) · strengths: 50mg, 100mg · Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab

MEXILETINE HCL

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 100mg, 200mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:04 and 9 more
Full class listing Related classes: 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors

Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN 24:08 Hypotensive Drugs (For Diuretics See 40:28)

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab

CILAZAPRIL & HYDROCHLOROTHIAZIDE

· 2 products · General benefit · strengths: 5mg/12.5mg · Tab

CLONIDINE HCL

· 17 products · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) · strengths: 0.025mg, 0.1mg, 0.2mg · Tab

DOXAZOSIN MESYLATE

· 12 products · Listed, not a benefit (3), General benefit (9) · strengths: 1mg, 2mg, 4mg · Tab

ENALAPRIL MALEATE

· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

FELODIPINE

· 12 products · General benefit (10), Listed, not a benefit (2) · strengths: 2.5mg, 5mg, 10mg · ER Tab, SR Tab

FOSINOPRIL SODIUM

· 12 products · Listed, not a benefit (2), General benefit (10) · strengths: 10mg, 20mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08 and 35 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: angina resulting from coronary artery spasm
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. NIFEDIPINE · General benefit (5), Listed, not a benefit (3) 1 INDICATIONS NIFEDIPINE (nifedipine capsules) is indicated for: • Management of angina resulting from coronary artery spasm. PM: https://pdf.hres.ca/dpd_pm/00073685.PDF; date JUN 16, 2010; DIN 00725110; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS AA-VERAP (verapamil hydrochloride tablets) is indicated for: • Chronic stable angina of effort. • Angina resulting from coronary artery spasm. • Obstructive hypertrophic cardiomyopathy, where surgery is not otherwise indicated. • Atrial fibrillation or flutter with rapid ventricular response not otherwise controllable with digitalis preparations. • Follow-up treatment to the use of injectable verapamil hydrochloride in paroxysmal supraventricular tachycardia. • Treatment of mild to moderate essential hypertension. Concomitant use of verapamil hydrochloride with a diuretic or an angiotensin converting enzyme inhibitor has been shown to be compatible and to have additive blood pressure lowering effects. 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (≥65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. Caution should be exercised when verapamil hydrochloride is admi… https://pdf.hres.ca/dpd_pm/00082059.PDF PM date: JUN 30, 1989 Source product: AA-VERAP; DIN 00782483; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

AA-Verap · DIN 00782483 Shortage status: active shortage (reported 2026-09-01, estimated to end 2026-09-25, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00782483

Check this DIN again

Apo-Verap SR · DIN 02246894 Shortage status: active shortage (reported 2015-04-17, last updated 2019-12-04) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246894

Check this DIN again

Isoptin SR · DIN 01934317 Shortage status: active shortage (reported 2020-08-10, last updated 2020-08-12) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01934317

Check this DIN again

Mylan-Verapamil SR · DIN 02450488 Shortage status: active shortage (reported 2022-09-07, last updated 2024-02-22) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02450488

Check this DIN again

Isoptin SR · DIN 00742554 Shortage status: active shortage (reported 2020-01-24, last updated 2021-08-31) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00742554

Check this DIN again

Mylan-Verapamil SR · DIN 02450496 Shortage status: active shortage (reported 2022-09-07, last updated 2023-03-27) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02450496

Check this DIN again

Apo-Verap SR · DIN 02246893 Shortage status: active shortage (reported 2015-04-17, last updated 2019-12-04) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246893

Check this DIN again

Mylan-Verapamil · DIN 02237921 Shortage status: discontinued (2024-04-11, reported by MYLAN PHARMACEUTICALS ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02237921

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Isoptin SR, Mylan-Verapamil SR, Apo-Verap SR, Isoptin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026